WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998052603) AN INFLUENZA ENVELOPED DNA VACCINE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/052603    International Application No.:    PCT/EP1998/003050
Publication Date: 26.11.1998 International Filing Date: 22.05.1998
Chapter 2 Demand Filed:    21.12.1998    
IPC:
A61K 9/00 (2006.01), A61K 9/127 (2006.01), A61K 39/145 (2006.01), A61K 39/165 (2006.01), A61K 48/00 (2006.01)
Applicants: SCHWEIZ. SERUM- & IMPFINSTITUT BERN [CH/CH]; Postfach 2707, CH-3001 Bern (CH) (For All Designated States Except US).
CUSI, Maria, Grazia [IT/IT]; (IT) (For US Only).
GLÜCK, Reinhard [CH/CH]; (CH) (For US Only).
WÄLTI, Ernst [CH/CH]; (CH) (For US Only)
Inventors: CUSI, Maria, Grazia; (IT).
GLÜCK, Reinhard; (CH).
WÄLTI, Ernst; (CH)
Agent: VOSSIUS & PARTNER; Siebertstrasse 4, D-81675 München (DE)
Priority Data:
97108390.2 23.05.1997 EP
Title (EN) AN INFLUENZA ENVELOPED DNA VACCINE
(FR) VACCIN COMPRENANT DE L'ADN A ENVELOPPE DU VIRUS DE LA GRIPPE
Abstract: front page image
(EN)Described are virosomes comprising cationic lipids, biologically active influenza hemagglutinin protein or biologically active derivatives thereof and nucleic acids encoding antigens from pathogenic sources in their insides, preferably antigens from mumps virus wherein said antigens are derived from conserved external and internal proteins of said virus. Provided are virosomes which may advantageously be formulated as vaccines capable of inducing strong neutralizing antibody and cytotoxic T cell responses as well as protection to pathogenic sources such as a mumps virus. Furthermore, vaccines comprising recombinant DNA derived from DNA encoding conserved external and internal proteins from mumps virus are described.
(FR)L'invention concerne des virosomes comprenant des lipides cationiques, de la protéine d'hémagglutinine de la grippe biologiquement active, ou des dérivés biologiquement actifs de ces derniers, et des acides nucléiques codant des antigènes à partir de sources pathogènes dans leurs intérieurs, de préférence, des antigènes provenant du virus des oreillons. Ces antigènes sont dérivés de protéines externes et internes conservées de ce virus. L'invention traite aussi de virosomes qui peuvent être formulés, de manière avantageuse, comme vaccins permettant d'induire des réponses des lymphocytes T cytotoxiques et des anticorps à forte neutralisation, ainsi qu'une protection contre les sources pathogènes comme le virus des oreillons. En outre, l'invention a pour objet des vaccins comprenant de l'ADN de recombinaison dérivés de l'ADN codant des protéines internes et externes conservées, provenant du virus des oreillons.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)